Globeflex Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Globeflex Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,044	Closed	-$1.1M	–	492
2024 Q3	$1.1M	Hold	1,044	–	–	0.11%	171
2024 Q2	$1.1M	Hold	1,044	–	–	0.11%	164
2024 Q1	$1M	Hold	1,044	–	–	0.1%	184
2023 Q4	$917K	Hold	1,044	–	–	0.09%	199
2023 Q3	$859K	Hold	1,044	–	–	0.1%	194
2023 Q2	$750K	Hold	1,044	–	–	0.08%	213
2023 Q1	$858K	Hold	1,044	–	–	0.1%	203
2022 Q4	$753K	Hold	1,044	–	–	0.1%	211
2022 Q3	$719K	Hold	1,044	–	–	0.12%	210
2022 Q2	$617K	Sell	1,044 -71	-6%	-$46.2K	0.15%	194
2022 Q1	$779K	Hold	1,115	–	–	0.16%	179
2021 Q4	$704K	Buy	1,115 +807	+262%	+$496K	0.14%	207
2021 Q3	$186K	Buy	308 +102	+50%	+$63.3K	0.04%	338
2021 Q2	$115K	Hold	206	–	–	0.02%	403
2021 Q1	$97K	Buy	206 +64	+45%	+$31.2K	0.02%	415
2020 Q4	$69K	Hold	142	–	–	0.01%	426
2020 Q3	$79K	Buy	142 +78	+122%	+$47.3K	0.02%	416
2020 Q2	$40K	Hold	64	–	–	0.01%	444
2020 Q1	$31K	Buy	+64	New	+$26.4K	0.01%	443

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Globeflex Capital's REGN Position: Q4 2024 in Review

Globeflex Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 1,044 shares — an estimated $1.1M sold.

Globeflex Capital first reported a position in REGN in Q1 2020 and held it in 19 quarters. The position peaked at $1.1M in Q3 2024. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Globeflex Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Globeflex Capital sold 1,044 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $1.1M.
Globeflex Capital first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 19 quarters.
Globeflex Capital's Regeneron Pharmaceuticals position peaked at $1.1M in Q3 2024.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Globeflex Capital's 13F filing for Q4 2024, filed 10 Feb 2025.